Acquiring Company
Asahi Kasei Corporation
Acquired Company
AiCuris Anti-infective Cures AG
Tokyo
WuppertalBiotechnologyHealth CareBiotechnologyHealth CareTherapeuticsDescription
Asahi Kasei is set to acquire Aicuris for €780 million to enhance its portfolio in infectious disease treatments. This acquisition will enable Asahi Kasei to expand its research and development capabilities and improve product commercialization. Aicuris' strong focus on antiviral therapies aligns with Asahi Kasei's strategic goals. The all-cash transaction is aimed at integrating the strengths of both companies to address critical patient needs.
Quick answer
Asahi Kasei Corporation is acquiring AiCuris Anti-infective Cures AG for $843.3 million, announced February 26, 2026. Asahi Kasei Corporation is based in Tokyo, Tokyo, Japan.
- How much did Asahi Kasei Corporation pay for AiCuris Anti-infective Cures AG?
- The reported deal value is $843.3 million.
- What does Asahi Kasei Corporation do?
- Asahi Kasei Corporation is a multinational Japanese company offering a diversified range of products and providing services across various sectors including chemicals, homes, and health care.
- Where are Asahi Kasei Corporation and AiCuris Anti-infective Cures AG based?
- Asahi Kasei Corporation is based in Tokyo, Tokyo, Japan. AiCuris Anti-infective Cures AG is based in Wuppertal, North Rhine Westphalia, Germany.
- Who are the decision-makers at Asahi Kasei Corporation?
- Fundz holds 1 contact at Asahi Kasei Corporation. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Cyclerion to merge with Korsana Biosciences (April 1, 2026)
- Aurinia acquires Kezar Life Sciences for $6.955/share (March 30, 2026)
- Gilead to acquire Ouro Medicines for $2 billion, $2B (March 23, 2026)
- GLAUKOS Corp acquires Mobius Therapeutics for $12.4M, $12M (February 23, 2026)
- Sensei Biotherapeutics acquires Faeth Therapeutics (February 18, 2026)
- Lifeward acquires Oratech Pharmaceuticals for $47M, $47M (April 3, 2026)
Who to call at Asahi Kasei Corporation, and when
When Asahi Kasei Corporation changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Asahi Kasei Corporation raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Asahi Kasei Corporation, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Asahi Kasei Corporation. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Asahi Kasei Corporation makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired AiCuris Anti-infective Cures AG?
AiCuris Anti-infective Cures AG was acquired by Asahi Kasei Corporation, based in Tokyo. The deal was reported on February 26, 2026. Asahi Kasei Corporation is a multinational Japanese company offering a diversified range of products and providing services across various sectors including chemicals, homes, and health care. Asahi Kasei Corporation is privately held and operates in Biotechnology.
When did Asahi Kasei Corporation acquire AiCuris Anti-infective Cures AG?
Asahi Kasei Corporation's acquisition of AiCuris Anti-infective Cures AG was reported on February 26, 2026. Asahi Kasei is set to acquire Aicuris for €780 million to enhance its portfolio in infectious disease treatments. This acquisition will enable Asahi Kasei to expand its research and development capabilities and improve product commercialization. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does AiCuris Anti-infective Cures AG do?
AiCuris is meeting the needs of the growing population of immunocompromised people who require precise therapies to effectively treat infection. It is privately held, operating in Biotechnology, and is based in Wuppertal.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.